Digest Network Come funziona
Network
/
Società
Pr
Non verificato

Prilenia Therapeutics B.V.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

8 comunicati stampa

Guarda tutti i comunicati
10/10/2025
Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress
Fonte
Prilenia Therapeutics B.V.
Emittente
Business Wire
1.00
0
06/10/2025
Multimedialità
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Industria
Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting
Fonte
Prilenia Therapeutics B.V.
Emittente
Business Wire
1.00
0
05/09/2025
Multimedialità
Biotecnologia
Farmaceutica
Libri/Editoria
Sanità
Salute
Comunicazione
Medicina - Varie
Analisi di mercato
Industria
Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression
Fonte
Prilenia Therapeutics B.V.
Emittente
Business Wire
1.00
0
25/07/2025
Multimedialità
Salute
Scienza
Farmaceutica
Biotecnologia
Industria
Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease
Fonte
Prilenia Therapeutics B.V.
Emittente
Business Wire
1.00
0
28/04/2025
Mercato del lavoro
Industria
Salute
Scienza
Farmaceutica
Biotecnologia
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets
Fonte
Prilenia Therapeutics B.V.
Emittente
Business Wire
1.00
0
05/11/2024
Eventi
Industria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Prilenia to Present Pridopidine Data at the Huntington Study Group (HSG) 2024 Congress
Fonte
Prilenia Therapeutics B.V.
Emittente
Business Wire
1.00
0
19/09/2024
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
Fonte
Prilenia Therapeutics B.V.
Emittente
Business Wire
1.00
0
03/09/2024
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
Fonte
Prilenia Therapeutics B.V.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0